Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$273.29 USD

273.29
552,903

+1.58 (0.58%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $273.28 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons Why You Should Invest in ResMed (RMD) Stock Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.

Zacks Equity Research

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCG

Zacks Equity Research

ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany

by Zacks Equity Research

ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.

Zacks Equity Research

Phibro (PAHC) Up 7.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline

by Zacks Equity Research

Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.

Zacks Equity Research

ResMed (RMD) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

by Urmimala Biswas

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Zacks Equity Research

Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IMCG

Zacks Equity Research

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

Zacks Equity Research

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

by Zacks Equity Research

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.

Zacks Equity Research

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

by Zacks Equity Research

ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.

Zacks Equity Research

ResMed (RMD) Q2 Earnings Meet Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Surprise Coming for ResMed (RMD) This Earnings Season?

by Zacks Equity Research

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Down 9.2% in 4 Weeks, Here's Why You Should You Buy the Dip in ResMed (RMD)

by Zacks Equity Research

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Walgreens Boots (WBA) Q1 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research

Walgreens Boots' (WBA) revenues increased year over year in the fiscal first quarter, driven by COVID-19 vaccinations and testing.

Zacks Equity Research

Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.

Zacks Equity Research

ABT or RMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ABT vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Zacks Equity Research

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Zacks Equity Research

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Zacks Equity Research

ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.